Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer By Ogkologos - April 21, 2026 178 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Qué debe saber sobre las pruebas de ADN en el hogar... February 8, 2023 Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab... July 9, 2021 Enfortumab Vedotin Approved for Recurrent Bladder Cancer January 14, 2020 Lawmaker Dad Raises Awareness For RSV, An Illness He’d Never Heard... November 20, 2019 Load more HOT NEWS Activity and Manageable Toxicity of Pembrolizumab in Some Rare and Ultrarare... When You Have Cancer and You’re a Parent: “Your Stories” Podcast Tepotinib Shows Activity in Advanced NSCLC with a MET Exon 14... Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary...
